Boston to Acquire Baylis for ~$1.75B


  • Boston has entered into a definitive agreement to acquire Baylis for $1.75B up front. The transaction is anticipated to close in Q1’22
  • The acquisition will bolster Boston’s electrophysiology and structural heart product portfolios with the addition of Baylis’ platforms i.e., NRG and VersaCross Transseptal that uses radiofrequency to access the left side of the heart
  • The platforms are designed for use in left-sided diagnostic, ablation, mitral, and LAAC procedures. Baylis has received US FDA’s 510(k) clearance for the NRG & VersaCross platform in 2008 & 2020 respectively

Click here to read full press release/ article | Ref: Boston Scientific | Image: Star Tribune

The post Boston to Acquire Baylis for ~$1.75B first appeared on PharmaShots.